Assembly Biosciences, Inc.: Focused on targeting hepatitis B virus (HBV) with a portfolio of potent, oral core inhibitors, that have the potential to increase cure rates for chronically infected patients. Lead candidate 731 is in Phase 2 – has demonstrated a favorable safety profile, and decreases in cccDNA population with patients expected to be withdrawn from treatment in 2020 and followed for sustained viral DNA suppression off therapy. 2158 is expected to complete Phase 1b in Q1 2020.
Based in...
Clinical Stage
Phase l or ll
Disease Space
Anti-infectives, Antivirals, Gastrointestinal, Infectious Disease
Public, USA
Market Cap
100MM - 500MM
11711 North Meridian Street
Suite 310
Carmel, IN 46032
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Solebury Trout Management Access: SF 2020

San Francisco, CA, United States, January 13 – January 16, 2020

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2019 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.